BioToxTech Co

BioToxTech Co Capital Intensity

The Capital Intensity Ratio of BioToxTech Co (086040.KQ) as of Nov 12, 2026 is 279.92 %. In the previous year, Capital Intensity Ratio was 329.43 % — a change of -15.03% (lower).

Capital Intensity

279.92 %

YoY

-15.03%

Last updated:

Capital Intensity Ratio of BioToxTech Co is 2025 279.92 % . Capital Intensity Ratio of BioToxTech Co was 2024 329.43 % . It decreases by -15.03% lower compared to the previous year.

The BioToxTech Co Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
231.73 KRW
Jan 1, 2019
232.75 KRW
Jan 1, 2020
240.86 KRW
Jan 1, 2021
277.35 KRW
Jan 1, 2022
337.07 KRW
Jan 1, 2023
450.60 KRW
Jan 1, 2024
329.43 KRW
Jan 1, 2025
279.92 KRW
The BioToxTech Co Capital Intensity history
YEARCapital IntensityYoY
279.92 %-15.03%
329.43 %-26.89%
450.60 %+33.68%
337.07 %+21.53%
277.35 %+15.15%
240.86 %+3.48%
232.75 %+0.44%
231.73 %-0.89%
233.80 %+8.39%
215.70 %-20.73%
272.11 %-14.17%
317.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Capital Intensity Ratio of BioToxTech Co is 279.92 % in 2025.

Capital Intensity Ratio of BioToxTech Co changed from 329.43 % to 279.92 %, representing a -15.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's BioToxTech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — BioToxTech Co

All Key Metrics — BioToxTech Co